|
EP0180398A1
(en)
|
1984-10-26 |
1986-05-07 |
The Regents Of The University Of California |
Synthesis of beta-lactam
|
|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
|
CA2058975C
(en)
|
1990-10-30 |
2000-06-06 |
Shuichi Kasai |
Antiinflammatory gel preparation
|
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
|
ATE283278T1
(de)
|
1996-06-07 |
2004-12-15 |
Astrazeneca Ab |
Peptid derivate
|
|
US5959075A
(en)
|
1996-08-02 |
1999-09-28 |
Zymogenetics, Inc. |
Testis-specific insulin homolog polypeptides
|
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
|
WO1999024584A1
(en)
|
1997-11-12 |
1999-05-20 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
|
WO2000027790A1
(en)
|
1998-11-11 |
2000-05-18 |
Smithkline Beecham P.L.C. |
Mutilin compounds
|
|
AU1724000A
(en)
|
1998-11-12 |
2000-05-29 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
|
AU1922301A
(en)
|
1999-11-17 |
2001-05-30 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
|
AU782678B2
(en)
|
2000-02-01 |
2005-08-18 |
Agy Therapeutics, Inc. |
Interaction of NMDA receptor with protein tyrosine phosphatase
|
|
JP2001261679A
(ja)
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
|
|
WO2001096606A2
(en)
|
2000-06-14 |
2001-12-20 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
|
JP2004500874A
(ja)
|
2000-06-22 |
2004-01-15 |
ニクシス ニューロセラピーズ インコーポレーティッド |
低酸素症および関連状態の治療のための神経活性ペプチド
|
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
|
WO2002047535A2
(en)
|
2000-12-14 |
2002-06-20 |
Nyxis Neurotherapies, Inc. |
High throughput assay to detect inhibitors of the map kinase pathway
|
|
AU2002248553A1
(en)
|
2001-03-07 |
2002-09-24 |
Cognetix, Inc |
Linear y-carboxyglutamate rich conotoxins
|
|
AU2002255705A1
(en)
|
2001-03-12 |
2002-09-24 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
|
US20030022253A1
(en)
|
2001-07-25 |
2003-01-30 |
Nyxis Neurotherapies, Inc. |
Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
|
|
ATE451373T1
(de)
|
2002-07-05 |
2009-12-15 |
Targacept Inc |
N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
CA2573951A1
(en)
|
2003-07-18 |
2005-01-27 |
Virochem Pharma Inc. |
Spiro compounds and methods for the modulation of chemokine receptor activity
|
|
EP1660634A4
(en)
|
2003-08-08 |
2009-02-18 |
Burnham Inst |
P16-mediated regulation of NMDA receptors
|
|
WO2005020973A2
(en)
|
2003-08-29 |
2005-03-10 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
|
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
|
US20070275990A1
(en)
|
2003-11-13 |
2007-11-29 |
Ono Pharmaceutical Co., Ltd. |
Heterocyclic Spiro Compound
|
|
JP4762155B2
(ja)
|
2004-01-08 |
2011-08-31 |
エフ．ホフマン−ラ ロシュ アーゲー |
ジアザ−スピロピペリジン誘導体
|
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
|
CN101090902B
(zh)
|
2004-10-13 |
2013-05-29 |
默沙东公司 |
Cgrp受体拮抗剂
|
|
RS52471B
(sr)
|
2005-03-24 |
2013-02-28 |
Emory University |
Režimi doziranja za lečenje traumatske povrede mozga progesteronom
|
|
EP1945691A2
(en)
|
2005-08-26 |
2008-07-23 |
Wisconsin Alumni Research Foundation |
Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
|
|
AR059224A1
(es)
*
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
|
WO2007103719A2
(en)
|
2006-03-03 |
2007-09-13 |
Incyte Corporation |
MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
|
|
US7884080B2
(en)
|
2006-09-15 |
2011-02-08 |
Schering Plough Corporation |
Azetidinone derivatives and methods of use thereof
|
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
|
US20090054392A1
(en)
|
2007-08-20 |
2009-02-26 |
Wyeth |
Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
|
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
|
US9783851B2
(en)
|
2008-02-20 |
2017-10-10 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
|
|
MX2010013946A
(es)
|
2008-06-24 |
2011-02-15 |
Intervet Int Bv |
Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en ganado.
|
|
JP2011525521A
(ja)
|
2008-06-27 |
2011-09-22 |
ノイロサーチ アクティーゼルスカブ |
新規なテトラメチル置換ピペリジン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用
|
|
CA2732091A1
(en)
|
2008-08-07 |
2010-02-11 |
F. Hoffmann-La Roche Ag |
Process for the preparation of a macrocycle
|
|
GB0814991D0
(en)
|
2008-08-15 |
2008-09-24 |
Glaxo Group Ltd |
Compounds
|
|
WO2010033757A1
(en)
*
|
2008-09-18 |
2010-03-25 |
Naurex, Inc. |
Nmda receptor modulators and uses thereof
|
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
|
US8329904B2
(en)
|
2009-05-12 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
|
WO2011003064A2
(en)
|
2009-07-02 |
2011-01-06 |
Naurex, Inc. |
Methods of treating neuropathic pain
|
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
|
PL2485751T3
(pl)
|
2009-10-05 |
2014-10-31 |
Univ Northwestern |
GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
|
|
WO2011068927A2
(en)
|
2009-12-04 |
2011-06-09 |
Abbott Laboratories |
11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
|
|
BR112012020142A2
(pt)
|
2010-02-11 |
2020-08-18 |
Northwestern University |
moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos.
|
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
US8097634B2
(en)
|
2010-04-15 |
2012-01-17 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
|
CN102267995A
(zh)
|
2010-06-04 |
2011-12-07 |
艾琪康医药科技（上海）有限公司 |
一种制备二氮杂螺环化合物的方法
|
|
AR082633A1
(es)
|
2010-08-12 |
2012-12-19 |
Tetraphase Pharmaceuticals Inc |
Analogos de tetraciclina
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
WO2012125598A1
(en)
|
2011-03-14 |
2012-09-20 |
Boehringer Ingelheim International Gmbh |
Benzodioxane inhibitors of leukotriene production
|
|
EP3679931A3
(en)
|
2011-04-27 |
2020-10-14 |
Northwestern University |
Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
|
|
US9293690B2
(en)
|
2011-06-27 |
2016-03-22 |
Koninklijke Philips N.V. |
Ultrasound transducer assembly and method of manufacturing the same
|
|
DK3686194T3
(da)
|
2011-07-27 |
2021-11-22 |
Astrazeneca Ab |
2-(2,4,5-substitueret-anilino)pyrimidinforbindelser
|
|
ES2935352T3
(es)
|
2013-01-29 |
2023-03-06 |
Aptinyx Inc |
Moduladores de receptores NMDA de espiro-lactama y sus usos
|
|
MX375286B
(es)
|
2013-01-29 |
2025-03-06 |
Aptinyx Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos.
|
|
CN105026401A
(zh)
|
2013-01-29 |
2015-11-04 |
诺雷克斯股份有限公司 |
螺-内酰胺nmda受体调节剂及其用途
|
|
BR112015018094A2
(pt)
|
2013-01-29 |
2017-07-18 |
Naurex Inc |
moduladores de receptor nmda de espiro-lactama e usos dos mesmos
|
|
JP6419087B2
(ja)
|
2013-01-29 |
2018-11-07 |
アプティニックス インコーポレイテッド |
スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
GB201416346D0
(en)
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
|
KR102128675B1
(ko)
|
2016-05-19 |
2020-06-30 |
앱티닉스 인크. |
스피로-락탐 nmda 수용체 조정제 및 그의 용도
|
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
|
SG11201900551WA
(en)
|
2016-08-01 |
2019-02-27 |
Aptinyx Inc |
Spiro-lactam nmda receptor modulators and uses thereof
|
|
KR102503590B1
(ko)
|
2016-08-01 |
2023-02-24 |
앱티닉스 인크. |
스피로-락탐 nmda 수용체 조정제 및 그의 용도
|
|
CA3031563C
(en)
|
2016-08-01 |
2023-12-05 |
Aptinyx Inc. |
Spiro-lactam nmda modulators and methods of using same
|
|
JP2019527235A
(ja)
|
2016-08-01 |
2019-09-26 |
アプティニックス インコーポレイテッド |
スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
|
|
EA201990424A1
(ru)
|
2016-08-01 |
2019-08-30 |
Аптиникс Инк. |
Спиролактамовые модуляторы nmda-рецептора и их применение
|
|
SG11202007256PA
(en)
|
2018-01-31 |
2020-08-28 |
Aptinyx Inc |
Spiro-lactam nmda receptor modulators and uses thereof
|
|
PE20211455A1
(es)
|
2018-01-31 |
2021-08-05 |
Aptinyx Inc |
Moduladores del receptor nmda espiro-lactama y usos de los mismos
|
|
US20210308101A1
(en)
|
2019-11-11 |
2021-10-07 |
Aptinyx Inc. |
Methods of treating fibromyalgia
|
|
US12012413B2
(en)
|
2019-11-11 |
2024-06-18 |
Tenacia Biotechnology (Hong Kong) Co., Limited |
Methods of treating painful diabetic peripheral neuropathy
|
|
JP2023505155A
(ja)
|
2019-12-04 |
2023-02-08 |
アプティニックス インコーポレイテッド |
神経変性疾患に関連する認知障害を治療する方法
|